BRISBANE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing…
TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools…
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical…
ROCHESTER, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company…
Expect to complete patient enrollment in the randomized Phase 1/2a SIGNAL-AD Alzheimer’s study in April 2023 with topline data anticipated…
NORCROSS, Ga., March 30, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts…
PRESS RELEASE - REGULATED INFORMATION 29 March 2023, 07:00 CEST Biocartis To Publish 2022 Annual Report on 11 April 2023…
Proprietary bi-functional ADCs target and inhibit unique Delta receptor on tumor-associated Myeloid Derived Suppressor Cells (MDSCs); increasing tumor’s susceptibility to…
First TIL Therapy BLA Submission to U.S. Food and Drug AdministrationSAN CARLOS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Iovance…